ArticleOncology letters2025
Clinical significance of cachexia index determined by bioelectrical impedance analysis in patients with gastrointestinal cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design.Cancer reports (Hoboken, N.J.) · 2026Review
- Global Research Trends in Nutritional Management of Gastrointestinal Cancers: a 2004-2024 Bibliometric and knowledge-mapping Analysis.Journal of gastrointestinal cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cachexia is a complex disorder characterized by skeletal muscle loss, which may influence the prognosis of patients with cancer. The cachexia index (CXI) is a new index for cachexia. The present study aimed to assess whether the CXI determined by bioelectrical impedance analysis (BIA) is valuable for predicting survival in patients with gastrointestinal cancer. A total of 54 patients with gastrointestinal cancer undergoing BIA at the time of diagnosis at Fukuchiyama City Hospital (Kyoto, Japan) were retrospectively recruited. CXI values were calculated as follows: CXI=skeletal muscle index (SMI) × serum albumin concentration/neutrophil-to-lymphocyte ratio. The SMI was measured using BIA values. The patients were classified into low- and high-CXI groups. The median patient age was 72 years and 63.0% of patients were male. A total of 20 patients with colorectal cancer were enrolled, 12 with pancreatic cancer, 11 with gastric cancer, 6 with esophageal cancer, 4 with biliary tract cancer and 1 with liver cancer. The cumulative one-year overall survival (OS) rate was significantly worse in the low-CXI group compared with that in the high-CXI group (58.3 vs. 88.5%; P=0.012). By contrast, the SMI had no significant effect on OS. Thus, CXI values using BIA may predict survival in patients with gastrointestinal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.